These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23712600)

  • 1. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction.
    Bregar U; Jug B; Keber I; Cevc M; Sebestjen M
    Heart Vessels; 2014 May; 29(3):313-9. PubMed ID: 23712600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
    Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
    Nasser Figueiredo V; Vendrame F; Colontoni BA; Quinaglia T; Roberto Matos-Souza J; Azevedo Moura F; Coelho OR; de Faria EC; Sposito AC
    Clin Ther; 2014 Jun; 36(6):961-6. PubMed ID: 24768191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.
    Warnholtz A; Wild P; Ostad MA; Elsner V; Stieber F; Schinzel R; Walter U; Peetz D; Lackner K; Blankenberg S; Munzel T
    Atherosclerosis; 2009 May; 204(1):216-21. PubMed ID: 18822413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
    Brinton EA; Triscari J; Brudi P; Chen E; Johnson-Levonas AO; Sisk CM; Ruck RA; MacLean AA; Maccubbin D; Mitchel YB
    Lipids Health Dis; 2016 Jul; 15(1):116. PubMed ID: 27405296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release niacin (nicotinic acid)/laropiprant.
    Perry CM
    Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of extended-release niacin with laropiprant in high-risk patients.
    ; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
    N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
    Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
    Hamilton SJ; Chew GT; Davis TM; Watts GF
    Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
    Andrews TC; Whitney EJ; Green G; Kalenian R; Personius BE
    Am J Cardiol; 1997 Oct; 80(7):831-5. PubMed ID: 9381993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV; Fillaus K; Harris WS; Shearer GC
    Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.